Venus Concept Announces Completion of Common Stock Sale and Short-Form Merger
Rhea-AI Summary
Venus Concept (NASDAQ: VERO) completed a short-form merger, effective March 30, 2026, consolidating 100% ownership under funds managed by Madryn Asset Management and converting outstanding common shares into $0.04 cash per share, subject to appraisal rights and withholding.
The company earlier closed a $1.5 million common stock issuance to Madryn at $0.04 per share on March 26, 2026, and is now privately held to pursue strategic growth and product innovation.
Positive
- Short-form merger completed March 30, 2026
- $1.5 million gross proceeds from common stock issuance on March 26, 2026
- Consolidated ownership under Madryn enabling private, long-term focus
Negative
- All non-Madryn public shares converted to $0.04 cash per share
- Company is no longer publicly traded, reducing public liquidity
News Market Reaction – VERO
In the Apr 1 session, VERO declined 14.94%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 21 | Delisting announcement | Negative | -57.5% | Plan to voluntarily delist from Nasdaq and deregister with the SEC. |
| Nov 13 | Earnings results | Negative | -8.0% | Q3 2025 revenue decline, large GAAP loss and negative EBITDA reported. |
| Nov 10 | Regulatory clearance | Positive | +13.5% | FDA 510(k) clearance for Venus NOVA non-invasive treatment platform. |
| Oct 02 | Debt restructuring | Positive | -5.0% | Debt-to-equity exchange reducing total debt obligations by 24% versus 2024. |
| Oct 01 | Earnings scheduling | Neutral | -0.4% | Announcement of Q3 2025 earnings release date and conference call details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News tied to strategic or structural shifts (delisting, capital structure moves) has often led to sharp downside, while product-clearance news saw a positive reaction. Today’s going‑private premium differs by aligning upside with a major ownership transition.
Over the past six months, Venus Concept navigated major strategic and financial changes. A planned voluntary delisting and deregistration announced on Jan 21, 2026 saw shares drop 57.53%. Earlier, Q3 2025 results with revenue decline and sizable losses led to an 8.02% pullback. By contrast, FDA 510(k) clearance for Venus NOVA on Nov 10, 2025 triggered a 13.47% gain. A debt-to-equity exchange announced on Oct 2, 2025 modestly weakened the stock despite improving leverage. Today’s short-form merger and take-private terms cap this transition toward full Madryn ownership.
Key Terms
short-form merger regulatory
forward-looking statements regulatory
turnaround plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced the successful completion by affiliates of Madryn Asset Management, LP (“Madryn”) of a short-form merger transaction, pursuant to which
The completion of the transaction positions the Company to pursue its strategic growth initiatives, enhance product innovation, and further strengthen its commercial presence.
Prior to the transaction, Venus Concept raised gross proceeds of
“This transaction represents an exciting new chapter for the organization,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “With Madryn as our sole owner, we can take a long-term view of the business, focus on innovation and commercialization, and continue delivering best-in-class solutions to our customers worldwide. We look forward to accelerating growth with the benefit of a streamlined ownership structure.”
The transaction reflects a shared conviction between Venus Concept and Madryn regarding the Company’s growth potential and strategic opportunities across its core medical aesthetic platforms and global footprint.
“Madryn has supported Venus as an investor since 2016. Since that period, Venus has built a compelling portfolio of differentiated technologies and a strong global presence,” said Avinash Amin, M.D., Madryn’s Managing Partner. “We look forward to Venus pursuing its next phase of growth.”
About Venus Concept
Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 9 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus NOVA, Venus Versa, Venus Versa PRO, Venus Bliss, Venus Bliss MAX, Venus Viva, Venus Viva MD, Venus Legacy, Venus Velocity, Venus Epileve and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, Masters Special Situations, and Madryn Asset Management, L.P.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. In some cases, you can identify these statements by words such as such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements include, but are not limited to, statements about the Company’s common stock, the short form merger, and the continued implementation or feasibility of the Company’s turnaround plan and ability to achieve long-term financial stability. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which the Company operates and management's beliefs and assumptions and are not guarantees of future performance or developments and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this communication may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under Part II Item 1A—“Risk Factors” in our Quarterly Reports on Form 10-Q and Part I Item 1A—“Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this communication. Unless required by law, the Company does not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise.
Investor Relations Contact: ICR Healthcare on behalf of Venus Concept: Mike Piccinino, CFA VenusConceptIR@ICRHealthcare.com